Feature interview: Rethinking medications
health author interview 41 minutes ago
Breakthrough drugs are changing medicine, offering new hope in pill form. But the system meant to protect patients is under strain. The U.S. develops over 40% of new medications, and the FDA plays a central role in ensuring their safety. Harvard pharmacology professor Dr. Jerry Avorn says industry pressure has quietly weakened FDA standards, allowing risky or barely effective drugs to slip through. In his new book he reveals how this happened and shares practical advice for patients trying to make decisions about what we are willing to swallow. The book is called Rethinking Medications: Truth, Power, and the Drugs You Take.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RNZ News
a day ago
- RNZ News
Health Committee backs bill to extend hospital stays for new mums, but how much will it cost?
The bill also requires the lead maternity carer to let the mother know what she is eligible for. Photo: 123RF Parliament's Health Committee recommends the Pae Ora Amendment Bill - which would offer mothers and newborns a minimum three-day postnatal hospital stay - be passed without any changes. However, the committee's report also notes the cost to add capacity to the system could be over $100 million, plus up to $38.3 million in annual operational costs. The Pae Ora (Healthy Futures) (3 Day Postnatal Stay) Amendment Bill proposes the 48 hours of funded inpatient post-natal care currently available, be upped to 72 hours. The bill also requires the lead maternity carer to let the mother know what she is eligible for. In the report, the Health Committee said they had "no issues regarding the legislation's design to bring to the attention of the House". But the report said the Committee were "advised" that 175 additional beds would need to be added to the nation-wide system to manage the increase of inpatient care. The capital expenditure - the initial amount needed to set-up - was estimated at $100 million, while annual operational costs could range from $31.9 million and $38.3 million, the report said. The costs are based on 100 percent demand. As not all mothers would use the 72-hour entitlement, the overall cost would be lower, the report said. The majority of submitters were in favour of the bill. But the report said regardless of stance, submitters agreed that a 72-hour stay alone will not solve broader issues in the maternity sector. "They sought wider reforms , including resourcing, alongside any change to postnatal care entitlements," the report concluded. Labour Health spokesperson Ayesha Verrall. Photo: VNP/Louis Collins Labour's health spokesperson Ayesha Verrall called on the government to provide the funding needed to implement the changes. "Anything less is a cynical attempt to look like it cares about women's health while actually doing nothing," Verrall said. National MP Catherine Wedd - who put the bill forward - said funding decisions were yet to be made. "If the bill progresses, our focus will be on making sure any changes are realistic, well-planned and sustainable - so they can truly deliver for families and for our health system," she said in a written statement. National MP Catherine Wedd. Photo: RNZ / Angus Dreaver "Investing in postnatal care through this bill will yield long-term benefits for the health and wellbeing of mothers, babies and whānau across New Zealand." She said the government "absolutely" supported the goal of ensuring women have access to safe and high-quality postnatal care. The bill is set to go back to the House for further debate. Sign up for Ngā Pitopito Kōrero , a daily newsletter curated by our editors and delivered straight to your inbox every weekday .
RNZ News
a day ago
- RNZ News
Pharmac considers extension to free meningoccocal B vaccination programme
An estimated 100,000 pre-schoolers are still unprotected. Photo: Pharmac says it's exploring ways to extend a free meningoccocal B vaccine programme, with an estimated 100,000 eligible pre-schoolers still not protected. Meningitis prevention advocates have pressured health officials to continue the campaign, which is due to end on 31 August. Pharmac pharmaceuticals director Geraldine MacGibbon said Pharmac funds the meningococcal B vaccine for all children under the age of one. "In March 2023, Pharmac funded a catch-up programme for children under the age of five to better protect young New Zealanders from meningococcal B. "We understand that people are keen to see the catch-up period extended and we are actively exploring options for this." "We will keep interested groups, including the Meningitis Foundation, informed about any updates," MacGibbon said. According to the Meningitis Foundation Aotearoa New Zealand, meningococcal bacteria can cause meningococcal meningitis - inflammation of the meninges, the membrane lining of the brain and spinal cord - and/or septicaemia (blood poisoning). Foundation chair Gerard Rushton said the meningococcal B vaccination programme was initiated after a submission the foundation made to Parliament and an application to Pharmac. He said more than 400,000 doses were given out in the first 12 months of the campaign. "We're calling on Health New Zealand and the government to actually continue this programme, because we know it works. We know it will save lives. "We know it's going to take pressure off the already-stretched health system. "What we're saying is this campaign has been very successful and it's been proven that people want it, but there's still 100,000 of our tamariki that haven't been protected, so we're calling them to keep this programme going. "We're really concerned that this large sector of our community are going to miss out. The vaccination rates for our young are still far too low, but we need them to extend this programme, because we need to protect those 100,000 of our children who are still unvaccinated." A Health New Zealand spokesperson said it was are "responsible for the implementation of the programme". "Pharmac funds the meningococcal B catch-up programme and set the timeframe from 1 March 2023 to 31 August 2025." A Health New Zealand spokesperson said, as of 9 June 2025, 84 percent of eligible children under 15 months had at least one dose of the meningococcal B vaccine. "Whānau can access the meningococcal B vaccines from a range of places, including general practice, hauora Māori and Pacific providers, with many Wellchild Tamariki Ora Services, including Whānau Āwhina Plunket, offering immunisations. "There are also more than 122 pharmacies now offering the vaccine for children aged from three years. "The meningococcal B vaccination is a part of the national immunisation schedule. "As a part of the Government's Health Target, we are focused on lifting childhood immunisation rates and we are making good progress towards this goal," said the spokesperson. Meningitis Foundation Aotearoa New Zealand chair Gerard Rushton said his organisation didn't see a reason for the catch-up programme to be discontinued. "Māori and Pasifika are 4-5 times more likely to catch meningitis than the European population, so they are a higher risk at the moment. We struggle to understand why there's a vaccination programme at the moment that actually discriminates against them. "The full vaccination programme was that the babies are free, there was a catch-up programme for 13-month to 5-year-olds, and that first-year students in boarding schools, halls of residence, barracks or prisons could get it free." "We feel that discriminates against the biggest at-risk group we've got, which is our Māori and Pasifika, because they're under-represented at halls of residence and boarding schools," he said.
RNZ News
a day ago
- RNZ News
Pharmac consider extension to free vaccination programme
An estimated 100,000 pre-schoolers are still unprotected. Photo: SERGII IAREMENKO/SCIENCE PHOTO L Pharmac says it's exploring ways to extend a free meningoccocal B vaccine programme, with an estimated 100,000 eligible pre-schoolers still not protected. Meningitis prevention advocates have pressured health officials to continue the campaign, which is due to end on 31 August. Pharmac pharmaceuticals director Geraldine MacGibbon said Pharmac funds the meningococcal B vaccine for all children under the age of one. "In March 2023, Pharmac funded a catch-up programme for children under the age of five to better protect young New Zealanders from meningococcal B. "We understand that people are keen to see the catch-up period extended and we are actively exploring options for this." "We will keep interested groups, including the Meningitis Foundation, informed about any updates," MacGibbon said. According to the Meningitis Foundation Aotearoa New Zealand, meningococcal bacteria can cause meningococcal meningitis - inflammation of the meninges, the membrane lining of the brain and spinal cord - and/or septicaemia (blood poisoning). Foundation chair Gerard Rushton said the meningococcal B vaccination programme was initiated after a submission the foundation made to Parliament and an application to Pharmac. He said more than 400,000 doses were given out in the first 12 months of the campaign. "We're calling on Health New Zealand and the government to actually continue this programme, because we know it works. We know it will save lives. "We know it's going to take pressure off the already-stretched health system. "What we're saying is this campaign has been very successful and it's been proven that people want it, but there's still 100,000 of our tamariki that haven't been protected, so we're calling them to keep this programme going. "We're really concerned that this large sector of our community are going to miss out. The vaccination rates for our young are still far too low, but we need them to extend this programme, because we need to protect those 100,000 of our children who are still unvaccinated." A Health New Zealand spokesperson said it was are "responsible for the implementation of the programme". "Pharmac funds the meningococcal B catch-up programme and set the timeframe from 1 March 2023 to 31 August 2025." A Health New Zealand spokesperson said, as of 9 June 2025, 84 percent of eligible children under 15 months had at least one dose of the meningococcal B vaccine. "Whānau can access the meningococcal B vaccines from a range of places, including general practice, hauora Māori and Pacific providers, with many Wellchild Tamariki Ora Services, including Whānau Āwhina Plunket, offering immunisations. "There are also more than 122 pharmacies now offering the vaccine for children aged from three years. "The meningococcal B vaccination is a part of the national immunisation schedule. "As a part of the Government's Health Target, we are focused on lifting childhood immunisation rates and we are making good progress towards this goal," said the spokesperson. Meningitis Foundation Aotearoa New Zealand chair Gerard Rushton said his organisation didn't see a reason for the catch-up programme to be discontinued. "Māori and Pasifika are 4-5 times more likely to catch meningitis than the European population, so they are a higher risk at the moment. We struggle to understand why there's a vaccination programme at the moment that actually discriminates against them. "The full vaccination programme was that the babies are free, there was a catch-up programme for 13-month to 5-year-olds, and that first-year students in boarding schools, halls of residence, barracks or prisons could get it free." "We feel that discriminates against the biggest at-risk group we've got, which is our Māori and Pasifika, because they're under-represented at halls of residence and boarding schools," he said.
